Download MendeleyDesign, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
Xiang, Q., Wang, C., Wu, T., Zhang, C., Hu, Q., Luo, G., Hu, J., Zhuang, X., Zou, L., Shen, H., Wu, X., Zhang, Y., Kong, X., Liu, J., Xu, Y.(2022) J Med Chem 65: 785-810
- PubMed: 34962793
- DOI: https://doi.org/10.1021/acs.jmedchem.1c01864
- Primary Citation of Related Structures:
7EVJ, 7XNE - PubMed Abstract:
CREB (cyclic-AMP responsive element binding protein) binding protein (CBP) is a potential target for prostate cancer treatment. Herein, we report the structural optimization of a series of 1-(indolizin-3-yl)ethan-1-one compounds as new selective CBP bromodomain inhibitors, aiming to improve cellular potency and metabolic stability. This process led to compound 9g (Y08284), which possesses good liver microsomal stability and pharmacokinetic properties ( F = 25.9%). Furthermore, the compound is able to inhibit CBP bromodomain as well as the proliferation, colony formation, and migration of prostate cancer cells. Additionally, the new inhibitor shows promising antitumor efficacy in a 22Rv1 xenograft model (TGI = 88%). This study provides new lead compounds for further development of drugs for the treatment of prostate cancer.
Organizational Affiliation:
Guangdong Provincial Key Laboratory of Biocomputing, Joint School of Life Sciences, Guangzhou Institutes of Biomedicine and Health, Guangzhou Medical University, Chinese Academy of Sciences, Guangzhou 510530, China.
